ARWR
Price
$38.97
Change
-$1.50 (-3.71%)
Updated
Nov 19 closing price
Capitalization
5.39B
5 days until earnings call
Intraday BUY SELL Signals
FULC
Price
$11.51
Change
+$1.78 (+18.29%)
Updated
Nov 19 closing price
Capitalization
623.44M
98 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARWR vs FULC

Header iconARWR vs FULC Comparison
Open Charts ARWR vs FULCBanner chart's image
Arrowhead Pharmaceuticals
Price$38.97
Change-$1.50 (-3.71%)
Volume$2.88M
Capitalization5.39B
Fulcrum Therapeutics
Price$11.51
Change+$1.78 (+18.29%)
Volume$3.86M
Capitalization623.44M
ARWR vs FULC Comparison Chart in %
ARWR
Daily Signal:
Gain/Loss:
FULC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARWR vs. FULC commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and FULC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ARWR: $38.97 vs. FULC: $11.52)
Brand notoriety: ARWR: Notable vs. FULC: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 137% vs. FULC: 572%
Market capitalization -- ARWR: $5.39B vs. FULC: $623.44M
ARWR [@Biotechnology] is valued at $5.39B. FULC’s [@Biotechnology] market capitalization is $623.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileFULC’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • FULC’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and FULC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 2 TA indicator(s) are bullish while FULC’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 2 bullish, 6 bearish.
  • FULC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FULC is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -5.92% price change this week, while FULC (@Biotechnology) price change was +37.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

ARWR is expected to report earnings on Nov 25, 2025.

FULC is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($5.39B) has a higher market cap than FULC($623M). FULC YTD gains are higher at: 145.106 vs. ARWR (107.287). ARWR has higher annual earnings (EBITDA): -52.51M vs. FULC (-80.09M). ARWR has more cash in the bank: 900M vs. FULC (201M). FULC has less debt than ARWR: FULC (7.01M) vs ARWR (353M). ARWR has higher revenues than FULC: ARWR (573M) vs FULC (0).
ARWRFULCARWR / FULC
Capitalization5.39B623M865%
EBITDA-52.51M-80.09M66%
Gain YTD107.287145.10674%
P/E RatioN/AN/A-
Revenue573M0-
Total Cash900M201M448%
Total Debt353M7.01M5,035%
FUNDAMENTALS RATINGS
ARWR vs FULC: Fundamental Ratings
ARWR
FULC
OUTLOOK RATING
1..100
7121
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
39n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (28) in the null industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that FULC’s stock grew significantly faster than ARWR’s over the last 12 months.

FULC's Profit vs Risk Rating (97) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to ARWR’s over the last 12 months.

FULC's SMR Rating (94) in the null industry is in the same range as ARWR (95) in the Biotechnology industry. This means that FULC’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as FULC (36) in the null industry. This means that ARWR’s stock grew similarly to FULC’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for FULC (100) in the null industry. This means that ARWR’s stock grew significantly faster than FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRFULC
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 1 day ago
87%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 14 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signal:
Gain/Loss:
FULC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DBIVX11.13N/A
N/A
DWS Global Macro S
ITHTX58.35N/A
N/A
Hartford Capital Appreciation R5
RYTLX56.78N/A
N/A
Rydex Telecommunications A
GLPCX30.19N/A
N/A
Goldman Sachs MLP Energy Infras C
BPRRX14.30N/A
N/A
Boston Partners Long/Short Rsrch Inv

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
+18.40%
SLS - FULC
48%
Loosely correlated
-3.77%
TRDA - FULC
45%
Loosely correlated
-0.91%
BEAM - FULC
44%
Loosely correlated
-4.24%
SLDB - FULC
44%
Loosely correlated
+0.11%
ARWR - FULC
43%
Loosely correlated
-3.71%
More